Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
Figure 5
Plasma IL-17A levels and percentage of Th17 cells in treatment patients.
(A) Plasma levels of IL-17A in patients who achieved hematological remission (CR: 19.73 pg/ml and PR: 17.47 pg/ml) after fludarabine-containing protocols in comparison to non-responding patients (PD: 9.09 pg/ml). (B) percentages of Th17 cells in the patients with progressive disease (3.04%) and those with complete (4.08%) or partial remission (3.83%). CR – complete remission; PR - partial remission; PD – progressive disease.